MX2009002254A - Bifeprunox doses for treating schizophrenia. - Google Patents

Bifeprunox doses for treating schizophrenia.

Info

Publication number
MX2009002254A
MX2009002254A MX2009002254A MX2009002254A MX2009002254A MX 2009002254 A MX2009002254 A MX 2009002254A MX 2009002254 A MX2009002254 A MX 2009002254A MX 2009002254 A MX2009002254 A MX 2009002254A MX 2009002254 A MX2009002254 A MX 2009002254A
Authority
MX
Mexico
Prior art keywords
schizophrenia
bifeprunox
patient
treatment
doses
Prior art date
Application number
MX2009002254A
Other languages
Spanish (es)
Inventor
Antje A Winsemius
Luigi M Barbato
Nathan A Shapira
Roseline Pardue
Vries Michiel H De
Marc Debelle
Jens Heisterberg
Oestergard Jette Buch
Dorte Malling
Ellen B Christensen
Paul P Yeung
Sangeeta Raje
Jeff Paul
Saeed Ahmed
Michel Bourin
Daniel E Casey
Steven G Potkin
Mark Rapaport
John Newcomer
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Priority claimed from PCT/EP2007/058958 external-priority patent/WO2008025781A1/en
Publication of MX2009002254A publication Critical patent/MX2009002254A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure is directed to a daily dose of bifeprunox for the treatment of a patient with schizophrenia. Such dose is effectively used in methods for treating schizophrenia comprising administering to a patient a pharmaceutical composition comprising an effective amount of at least one bifeprunox compound, amongst other effects, resulting in a reduction of side effects associated with schizophrenia treatment such as: no weight gain, improvement of non-fasting triglyceride levels and/or total cholesterol levels. Treatment effects are e.g. a reduction of PANSS total score in a patient and an increase of the time to deterioration of schizophrenia and improvement of psychotic symptoms.
MX2009002254A 2006-08-31 2007-08-29 Bifeprunox doses for treating schizophrenia. MX2009002254A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06119936 2006-08-31
EP06120016 2006-09-01
PCT/EP2007/058958 WO2008025781A1 (en) 2006-08-31 2007-08-29 Bifeprunox doses for treating schizophrenia

Publications (1)

Publication Number Publication Date
MX2009002254A true MX2009002254A (en) 2009-07-24

Family

ID=40085736

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009002253A MX2009002253A (en) 2006-08-31 2007-08-29 Titration schedule for bifeprunox for treating schizophrenia and kits for use therein.
MX2009002254A MX2009002254A (en) 2006-08-31 2007-08-29 Bifeprunox doses for treating schizophrenia.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2009002253A MX2009002253A (en) 2006-08-31 2007-08-29 Titration schedule for bifeprunox for treating schizophrenia and kits for use therein.

Country Status (4)

Country Link
CN (1) CN101686978A (en)
AR (2) AR062561A1 (en)
MX (2) MX2009002253A (en)
TW (2) TW200829576A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115569123B (en) * 2022-12-08 2023-03-14 则正(济南)生物科技有限公司 Vorinosane fumarate tablet and preparation method thereof

Also Published As

Publication number Publication date
TW200817390A (en) 2008-04-16
CN101686978A (en) 2010-03-31
TW200829576A (en) 2008-07-16
AR062561A1 (en) 2008-11-19
AR063697A1 (en) 2009-02-11
MX2009002253A (en) 2009-06-04

Similar Documents

Publication Publication Date Title
NZ597193A (en) Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
NZ627238A (en) Stable pharmaceutical composition comprising ethyl eicosapentaenoate
EA201390409A1 (en) COMPOSITIONS WITH LOW DOSE OF PANCRELIPASE AND INTESTINAL-SOLUBLE COATING
MX2009011867A (en) Novel macrocyclic inhibitors of hepatitis c virus replication.
WO2009152189A8 (en) Low dose topiramate/phentermine compostion and methods of use thereof
MX2009008439A (en) Novel inhibitors hepatitis c virus replication.
NZ591810A (en) Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
MX2010002392A (en) Improved brimonidine compositions for treating erythema.
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2008050329A3 (en) Novel sirnas and methods of use thereof
MY148690A (en) Novel macrocyclic inhibitors of hepatitis c virus replication
MX344476B (en) Methods of treating pulmonary disorders with liposomal amikacin formulations.
MX2012003171A (en) Novel macrocyclic inhibitors of hepatitis c virus replication.
EA201270144A1 (en) COMBINED THERAPY FOR TREATMENT OF DIABETES
UA106209C2 (en) Choline cocrystal of 5-[(1z,2e)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidine acetic acid
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
WO2009134616A3 (en) Novel inhibitors of hepatitis c virus replication
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
BRPI0411098A (en) benzofuranocarboxamides, with pi3k activity, as therapeutic agents
MX2010009624A (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1.
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
WO2010033884A3 (en) Method for the treatment of radiation-induced neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant
MX2013002208A (en) Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal